CDT Quote, Financials, Valuation and Earnings

LENZ Therapeutics has a net margin of -- compared to Conduit Pharmaceuticals's net margin of --. Conduit Pharmaceuticals's return on equity of -- beat LENZ Therapeutics's return on equity of --.

Conduit Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand LENZ Therapeutics has an analysts' consensus of $44.50 which suggests that it could grow by 28.28%. Given that LENZ Therapeutics has higher upside potential than Conduit Pharmaceuticals, analysts believe LENZ Therapeutics is more attractive than Conduit Pharmaceuticals.

Conduit Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Conduit Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. Conduit Pharmaceuticals pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.

Conduit Pharmaceuticals quarterly revenues are --, which are smaller than LENZ Therapeutics quarterly revenues of --. Conduit Pharmaceuticals's net income of -$5.1M is higher than LENZ Therapeutics's net income of -$14.6M. Notably, Conduit Pharmaceuticals's price-to-earnings ratio is -- while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conduit Pharmaceuticals is -- versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Liminatus Pharma has a net margin of -- compared to Conduit Pharmaceuticals's net margin of --. Conduit Pharmaceuticals's return on equity of -- beat Liminatus Pharma's return on equity of --.

Conduit Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Conduit Pharmaceuticals has higher upside potential than Liminatus Pharma, analysts believe Conduit Pharmaceuticals is more attractive than Liminatus Pharma.

Conduit Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Conduit Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Conduit Pharmaceuticals pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.

Conduit Pharmaceuticals quarterly revenues are --, which are smaller than Liminatus Pharma quarterly revenues of --. Conduit Pharmaceuticals's net income of -$5.1M is higher than Liminatus Pharma's net income of --. Notably, Conduit Pharmaceuticals's price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conduit Pharmaceuticals is -- versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Maze Therapeutics has a net margin of -- compared to Conduit Pharmaceuticals's net margin of --. Conduit Pharmaceuticals's return on equity of -- beat Maze Therapeutics's return on equity of --.

Conduit Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Maze Therapeutics has an analysts' consensus of $23.00 which suggests that it could grow by 52.82%. Given that Maze Therapeutics has higher upside potential than Conduit Pharmaceuticals, analysts believe Maze Therapeutics is more attractive than Conduit Pharmaceuticals.

Conduit Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Maze Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Conduit Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Maze Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Conduit Pharmaceuticals pays -- of its earnings as a dividend. Maze Therapeutics pays out -- of its earnings as a dividend.

Conduit Pharmaceuticals quarterly revenues are --, which are smaller than Maze Therapeutics quarterly revenues of --. Conduit Pharmaceuticals's net income of -$5.1M is higher than Maze Therapeutics's net income of --. Notably, Conduit Pharmaceuticals's price-to-earnings ratio is -- while Maze Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conduit Pharmaceuticals is -- versus -- for Maze Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Oruka Therapeutics has a net margin of -- compared to Conduit Pharmaceuticals's net margin of --. Conduit Pharmaceuticals's return on equity of -- beat Oruka Therapeutics's return on equity of --.

Conduit Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Oruka Therapeutics has an analysts' consensus of $39.50 which suggests that it could grow by 180.74%. Given that Oruka Therapeutics has higher upside potential than Conduit Pharmaceuticals, analysts believe Oruka Therapeutics is more attractive than Conduit Pharmaceuticals.

Conduit Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oruka Therapeutics has a beta of -0.343, suggesting its less volatile than the S&P 500 by 134.274%.

Conduit Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. Conduit Pharmaceuticals pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.

Conduit Pharmaceuticals quarterly revenues are --, which are smaller than Oruka Therapeutics quarterly revenues of --. Conduit Pharmaceuticals's net income of -$5.1M is higher than Oruka Therapeutics's net income of -$21M. Notably, Conduit Pharmaceuticals's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conduit Pharmaceuticals is -- versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.